SecBot SecBot

NVCR

NovoCure Ltd
Nasdaq· Surgical & Medical Instruments & Apparatus· CIK 0001645113 Healthcare & Medical Devices
$11.30 −0.53 (−4.48%)
Nov 16 4:00 PM ET · prev $11.83
Market cap
$1.4B
Small cap
Consensus
Buy
69% Buy or better · 13 analysts
Median target
$20.00
+77% · range $15.00–52.00
1 year
+0.3%
from $11.27 · Nov 17
30 days
−24.1%
from $14.89
52-week range
$10.03–19.99
−43% from high · low Feb 9
Avg volume 20D
1.98M
Oct 29 spike 5.95M
Short interest
12.91M
≈11.1% of shares · +0.7%
Days to cover
6.0
at average volume
Insider net
−$2.7M
0 buyers · 14 sellers · since Mar 3
New fund stakes
0
Q3 2026 13F · 1 exit
Filing reports
20
analyzed by SecBot
SecBot read MIXED 8 reports · 90 days
Balance 1 bearish · 2 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 7/8 ·Next FDA decision date, Dec 31, 2026

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    14 insiders sold $2.7M.

  • InstitutionsBULLISH

    Q3 2026: 32 added (0 new), 11 trimmed or exited.

  • AnalystsBULLISH

    9 of 13 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.251 → −$0.214 over 90 days. 5 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +0.7% to 12.91M shares. 6.0 days to cover, ≈11.1% of shares.

  • TrendDOWNTREND

    23% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
1
exit
FundMoveSharesValue
Quantinno Capital Management LPADD4,223,461$67.4M
MACKENZIE FINANCIAL CORPDOUBLED1,176,709$18.8M
JPMORGAN CHASE & COTRIM967,478$15.6M
Qube Research & Technologies LtdADD920,744$14.7M
Empowered Funds, LLCTRIM621,157$9.9M
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUNDTRIM400,000$6.4M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPDOUBLED355,982$5.7M
FIRST TRUST ADVISORS LPDOUBLED335,392$5.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 69% rate it Buy or better
Strong Buy3Buy6Hold4Sell0Strong Sell0
12-month targets · 7 analysts

Price is below the lowest target. Median implies +77%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 10, 2026Ladenburg Thalmann
MAINTAIN
MAINTAINBuy
Nov 10, 2026Wedbush
MAINTAIN
MAINTAINNeutral
Oct 30, 2026Wells Fargo
MAINTAIN
MAINTAINEqual-Weight
Oct 30, 2026Evercore ISI Group
MAINTAIN
MAINTAINOutperform
Jul 24, 2026Wedbush
MAINTAIN
MAINTAINNeutral
Jul 23, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$2.7M
sold · 14 insiders
DateInsiderTypeValue
Nov 9, 2026
Brackmann Christoph
Chief Financial Officer
Nov 9, 2026
SELL$94.4K
Nov 9, 2026
Paravasthu Mukund
Chief Operating Officer
Nov 9, 2026
SELL$39.6K
Nov 2, 2026
Puri Michal Nath
Chief Human Resources Officer
Nov 2, 2026
SELL$8.7K
Jun 30, 2026
Leonard Frank X
Chief Executive Officer
Jun 30, 2026
AWARD$21.2K
Jun 30, 2026
Danziger Asaf
Director
Jun 30, 2026
AWARD$3.0K
Jun 30, 2026
Ben Arye Barak
General Counsel
Jun 30, 2026
AWARD$14.5K
Jun 30, 2026
Puri Michal Nath
Chief Human Resources Officer
Jun 30, 2026
AWARD$21.2K
Jun 4, 2026
Leonard Frank X
Chief Executive Officer
Jun 4, 2026
SELL$614.6K

Earnings setup

Estimates
−$0.21
EPS estimate, this quarter
+15%
estimate change, 90 days
5↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.21-$0.25–-$0.19+11.3%$189.7M
Next Q-$0.20-$0.25–-$0.13+9.3%$189.4M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

26 lobbying filings and 2 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
12,913,904
shares short
+0.7%
vs prior settlement
6.0
days to cover
≈11.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 12, 2026 SEC
Two NovoCure insiders, including the CFO and CHRO, sold shares in open-market transactions totaling $103K over a…
CLUSTER · Impact 2/10
Nov 9, 2026 SEC
Soleus Capital Master Fund filed an amended Schedule 13G disclosing a 8.1% passive stake in NovoCure as of September…
SC 13G/A · Impact 3/10
Nov 9, 2026 SEC
Christoph Brackmann, an officer of NovoCure, filed a Form 144 notice of intent to sell 7,343 shares of common stock…
144 · Impact 2/10
Nov 9, 2026 Insider
Brackmann Christoph sold 7,343 shares
Chief Financial Officer @ $12.86 ($94.4K)
Nov 9, 2026 Insider
Paravasthu Mukund sold 3,079 shares
Chief Operating Officer @ $12.86 ($39.6K)
Nov 2, 2026 Insider
Puri Michal Nath sold 660 shares
Chief Human Resources Officer @ $13.24 ($8.7K)
Oct 29, 2026 Earnings result
NVCR Q3 2026 Earnings: EPS $-0.09 (+63.9% vs est)
Sep 30, 2026 Inst.
Quantinno Capital Management LP · ADD
4,223,461 shares ($67.4M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Upcoming
Recent

SecBot reports

20 filings · 4 bullish · 3 bearish · 1 mixed · 12 neutral
All NVCR filing & press-release reports (20)